A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among ...

ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas. The first patient was dosed in the SKYBRIDGE ...

Scientists say these small health issues might be an early sign of lung cancer - As the NHS offers ‘revolutionary’ blood test ...

Table 1. Clinical Characteristics of Patients With NTRK-Rearranged Non–Small-Cell Lung Cancer Table 2. Molecular Characteristics of NTRK Rearrangements in Non–Small-Cell Lung Cancer Tumors Included in ...

Alecensa is used to treat non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Some types of lung cancer can be treated with a drug that works when it is combined ...